Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04030455
Title Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center

laryngeal squamous cell carcinoma


Cisplatin + Docetaxel + Pembrolizumab

Carboplatin + Docetaxel + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.